Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis

This study has been completed.
Information provided by (Responsible Party):
Kyowa Hakko Kirin Company, Limited Identifier:
First received: December 1, 2011
Last updated: November 1, 2012
Last verified: November 2012
This is a randomized, placebo-controlled, ascending single dose study of KHK4827 to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous or intravenous administration of KHK4827 in healthy male subjects or moderate to severe psoriasis patients.

Condition Intervention Phase
Drug: Placebo
Drug: KHK4827
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KHK4827 in Healthy Volunteers and Subjects With Moderate to Severe Psoriasis

Resource links provided by NLM:

Further study details as provided by Kyowa Hakko Kirin Company, Limited:

Primary Outcome Measures:
  • Safety [ Designated as safety issue: Yes ]
    • Adverse events
    • Clinical laboratory test data
    • Vital signs

Secondary Outcome Measures:
  • Plasma KHK4827 concentrations and pharmacokinetic parameters [ Time Frame: 16 time points up to 64 days ] [ Designated as safety issue: No ]

    To assess PK parameters which include

    • area under the plasma concentration versus time curve (AUC)
    • peak plasma concentration (Cmax)
    • t1/2
    • CL

Estimated Enrollment: 48
Study Start Date: November 2011
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: KHK4827 Drug: KHK4827
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Health volunteers

  • Able to provide written informed consent
  • Healthy male between 20 to 45 years of age, inclusive at the time of screening
  • Additional inclusion criteria apply

Psoriasis subjects

  • 20 to 70 years of age, inclusive at the time of screening
  • Active but clinically stable, plaque psoriasis
  • Psoriasis involving ≥10% of the body surface area
  • A minimum PASI score of ≥10 obtained during the screening period
  • Additional inclusion criteria apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01488201

Tokyo, Japan
Sponsors and Collaborators
Kyowa Hakko Kirin Company, Limited
  More Information

Responsible Party: Kyowa Hakko Kirin Company, Limited Identifier: NCT01488201     History of Changes
Other Study ID Numbers: 4827-001 
Study First Received: December 1, 2011
Last Updated: November 1, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Kyowa Hakko Kirin Company, Limited:

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases processed this record on October 25, 2016